Favrille plunges in pre-market trading, phase 3 trial failsShares of Favrille, Inc. (Nasdaq: FVRL) are getting pummeled in pre-market trading after the biopharmaceutical company said this morning that its phase 3 trial of Specifid following Rituxan in patients with follicular B-cell non-Hodgkin's lymphoma failed. As a result, the company said it is discontinuing development of Specifid and is evaluating steps to conserve cash and recognize value on its assets. Shares slumped 80%, or $1.39, to $0.35 in pre-market trading. For detailed price information and recent news stories about Favrille, click FVRL. spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer
|
Research
|
